Journal Browser

Go Edit a Special Issue


Special Issue Title:

Anticoagulation Practice in COVID-19 Associated Coagulopathy (CAC): The Unanswered Questions

Deadline for manuscript submissions: 20 October 2021

Print Special Issue Flyer (4)

Special Issue Editor

  • Guest Editor

    Dr. Mohamed H. AonE-MailWebsite

    Internal medicine department, Jahra hospital, Jahra city, Kuwait

    Interests: Internal medicine, Critical care medicine, COVID-19, Sepsis, Infectious diseases, Medical education

Special Issue Information

Since late 2019, the COVID-19 pandemic has affected millions of people globally with a wide range of manifestations ranging from asymptomatic infection to critical illness. The disease not only affects the lungs, but also affects other systems.

The COVID-19 associated coagulopathy (CAC) reflects a complex relation between inflammation and coagulation abnormalities with an underlying hypercoagulable state. Patients with severe COVID-19 can have high D-dimer and low platelets levels, which can confuse CAC with DIC. However, other coagulation parameters are different from DIC. Besides, COVID-19 is associated with hypercoagulability contrary to acute DIC which is usually associated with a bleeding tendency. The diagnostic evaluation of CAC is challenging because we do not know which coagulation parameter should be acted upon. D-dimer levels are associated with disease severity, but its impact on treatment decisions and dosing of anticoagulants is still under investigations. The intensity of anticoagulation used is still debated with some authorities recommending higher doses of anticoagulants in critically ill patients. The risk of thrombosis includes both venous and arterial sides which raises questions about the optimum strategy to prevent thrombosis and the role of antiplatelet drugs in COVID-19.

Management of COVID-19 patients who experience clotting of access lines or extracorporeal circuits while receiving prophylactic anticoagulants is still controversial. Decisions about post-discharge thromboprophylaxis, whether to use antiplatelets or anticoagulants, and the optimum dose and duration are still under investigations. Adding to the complexity of the situation, critically ill patients usually receive several medications that can interact with anticoagulants leading to inconsistent response, they have pharmacokinetic and pharmacodynamic variability which can lead to an increased potential for adverse events, and frequently undergo procedures that require interruption of their anticoagulation. Dealing with these dilemmas is a superadded challenge to physicians. In the era of COVID-19, we are faced with the uncertainty about the appropriate interventions to prevent and treat hypercoagulability associated with severe COVID-19 infections. Throughout history, the COVID-19 pandemic is one of the greatest challenges to our health care systems. Our response to the COVID-19 pandemic is to promote research in areas that need more studies to fill the knowledge gap.

This special issue focuses on CAC management dilemmas and is expected to attract the attention of many specialties including intensivists, hematologists, pulmonologists, infectious diseases specialists, internists, virologists, and clinical researchers. In the present special issue, we invite case reports or series, state-of-the-art review and original research articles focused on the pathophysiology, diagnosis, and treatment of CAC.


SARS-CoV-2, COVID-19, COVID-19 associated coagulopathy, Hypercoagulability, Coagulation disorders, Thrombosis, Anticoagulants, DOACs, Heparin, Bleeding

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Signa Viate is an international peer-reviewed open access journal published by MRE Press. As of January 2021, Signa Vitae will change to a bimonthly journal. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2021) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time